Pellegrino Crafa

Prof. Pellegrino Crafa

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2022 in Journal of Gastrointestinal and Liver Diseases
Verified
Journal Article
Open access
PDF file
MRMichele Russo
Michele Russo
PCPellegrino Crafa
Pellegrino Crafa
Simone GuglielmettiSimone Guglielmetti
Simone Guglielmetti
LFLorella Franzoni
Lorella Franzoni
WFWalter Fiore
Walter Fiore
FMFrancesco Di Mario
Francesco Di Mario
Burning mouth syndrome (BMS) is defined as “idiopathic orofacial pain with intraoral burning or dysesthesia recurring daily for more than 2 hours per day and more than 3 months, without any identifiable causative lesions, with or without somatosensory changes” in International Classification of Orofacial Pain, 2020. Worldwide prevalence of BMS was estimated to be 1.73% in population-based studies, while female and elderly are at higher risk of BMS. The aim of this narrative review is to clarify the main etiopathogenetic factors of BMS investigated so far in the scientific literature. There is growing evidence of an important role of peripheral neuropathology in BMS, supported by immunohistochemical studies which have demonstrated a significant loss of epithelial and subepithelial nerve fibers. Other possible etiopathogenetic factors emerging from literature are laryngopharyngeal reflux and hormonal and salivary changes related to aging and menopause. Finally, the role of the oral microbiota in BMS has not yet been thoroughly investigated. Further studies are necessary to investigate the probably multifactorial etiopathogenesis of primary BMS, a pathology which has a serious impact on the quality of life of our patients, a disease we find ourselves treating without the adequate therapy and the necessary knowledge.

30 October 2009 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
VPVladimiro Pietrini
Vladimiro Pietrini
FMFlavio Mozzani
Flavio Mozzani
PCPellegrino Crafa
Pellegrino Crafa
RSRoberto Sivelli
Roberto Sivelli
Filippo CademartiriFilippo Cademartiri
Filippo Cademartiri
GCGirolamo Crisi
Girolamo Crisi

17 December 2018
Verified
Journal Article
Open access
PCPellegrino Crafa
Pellegrino Crafa
MRMichele Russo
Michele Russo
CMChiara Miraglia
Chiara Miraglia
ABAlberto Barchi
Alberto Barchi
FMFlorenzo Moccia
Florenzo Moccia
FMFrancesco Di Mario
Francesco Di Mario
Chronic gastritis is a long-lasting disease that can lead to a loss of appropriate gastric glands. Gastritis, as term, apply to an inflammation of the stomach, histologically proven, sometimes with structural mucosal changes. Worldwide Helicobacter pylori's infection play a pivotal role as the main etiological effector of chronic active gastritis. H. p. is a bacterium with a selective tropism for the gastric mucosa, able to survive in a hostile environment for colonization of organisms other than itself, able to develop strategies for survival and for avoidance of the defence mechanisms, causing inflammatory changes, that vary from asymptomatic mild gastritis to more severe injury such as peptic ulcer as well as premalignant lesions and malignant tumours. The pattern and distribution of gastritis strongly correlate with these sequelae and chronic atrophic gastritis with intestinal metaplasia is now assessed as a precancerous lesion with definite risk of evolution towards intraepithelial lesions of both low and high grade, as expected in the model of the Correa's cascade. In fact, the leading complication of chronic gastritis remains its close correlation with gastric cancer being biologically linked to H. pylori infection, nowadays known as a class I carcinogen. Gastric carcinogenesis is due to environmental factors, as well as to bacterial strain, host responses and gastric mucosal microbiome dysbiosis. Since, individual patients show different gastric cancer risk, it is mandatory to identify patients at risk of developing gastric cancer to offer a targeted search for lesions with a more rapid development of neoplasm liable, in an early phase, to a less destructive treatment. OLGA staging system is the most reliable and powerful system that allow the recognition of patient with a higher risk of developing gastric cancer.

6 December 2017 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
AFAlessandro Fugazza
Alessandro Fugazza
BBBarbara Bizzarri
Barbara Bizzarri
FGFederica Gaiani
Federica Gaiani
MMMarco Manfredi
Marco Manfredi
AGAlessia Ghiselli
Alessia Ghiselli
GDGian Luigi de'Angelis
Gian Luigi de'Angelis
The role of endoscopic ultrasound (EUS) in the management of pancreatobiliary and digestive diseases is well established in adults, but it remains limited in children. The aim of this study was to evaluate the feasibility, safety, and clinical impact of EUS use in children. This is a retrospective analysis of a prospectively acquired database of consecutive pediatric (< 18 years) patients presenting an indication for EUS for pancreatobiliary and gastrointestinal disorders. Between January 2010 and January 2016, 47 procedures were performed in 40 children (mean age of 15.1 ± 4.7 years; range 3–18). The majority of EUS (n = 32; 68.1%) were performed for pancreatobiliary and upper gastrointestinal pathologies, including suspected common bile duct stones (CBDs), acute biliary pancreatitis, recurrent/chronic pancreatitis, cystic pancreatic mass, recurrent hypoglycemia, duodenal polyp, gastric submucosal lesion, and perigastric abscess. In only 2 out of 18 children with suspected CBDs or acute biliary pancreatitis, EUS confirmed CBDs. EUS-guided fine needle aspiration was performed in 3 (6.4%) patients. Fifteen (31.9%) procedures were performed for lower gastrointestinal tract disorders, including suspected anal Crohn’s disease, fecal incontinence, and encopresis. Overall, EUS had a significant impact on the subsequent clinical management in 87.2% of patients. The present findings were consistent with results observed in the current relevant literature and support EUS as a safe and feasible diagnostic and therapeutic tool, which yields a significant clinical impact in children with pancreatobiliary and gastrointestinal disorders.

8 January 2022 in Helicobacter
Verified
Journal Article
Closed access
PDF file
FMFrancesco Di Mario
Francesco Di Mario
PCPellegrino Crafa
Pellegrino Crafa
ABAlberto Barchi
Alberto Barchi
LFLorella Franzoni
Lorella Franzoni
MFMarilisa Franceschi
Marilisa Franceschi
MRMassimo Rugge
Massimo Rugge

20 August 2010 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
JOJeremiah V. Ojeaburu
Jeremiah V. Ojeaburu
TITetsuhide Ito
Tetsuhide Ito
PCPellegrino Crafa
Pellegrino Crafa
CBCesare Bordi
Cesare Bordi
RJRobert T Jensen
Robert T Jensen